Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Thorsten Stuehmer"'
Autor:
Filip Garbicz, Sonia Debek, Anna Szumera-Ciećkiewicz, Joanna Barankiewicz, Dorota Komar, Michał Pawlak, Aleksandra Matrejek, Thorsten Stuehmer, Aleksander Salomon-Perzynski, Agata Malenda, Julia Ostrowska, Julia Dudkiewicz, Krzysztof Brzózka, Tomasz Rzymski, Daniela Bellarosa, Ewa Lech-Marańda, Monika Prochorec-Sobieszek, Zofia Pilch, Dominika Nowis, Jakub Golab, Helen Tanton, Teru Hideshima, David M. Dorfman, Irena Misiewicz-Krzeminska, Tomasz Sewastianik, Ruben D. Carrasco, Maciej Szydlowski, Przemyslaw Juszczynski
Publikováno v:
Blood. 140:4189-4190
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d845f85e0b053ff1b1731dfa44bb2cdb
https://doi.org/10.1182/blood-2022-168770
https://doi.org/10.1182/blood-2022-168770
Autor:
Andreas Schlosser, Sabrina Kraus, Friederike Berberich-Siebelt, Ellen Leich, Umair Munawar, Hermann Einsele, Daniela Bruennert, Michael Hudecek, Torsten Steinbrunn, Manik Chatterjee, Pooja Shah, Ralf C. Bargou, Thorsten Stuehmer
Publikováno v:
Blood. 138:1587-1587
Introduction The CD200/CD200 receptor (CD200R) axis is known to exert immunoregulatory effects in myeloid-derived cells and constitutes a putative immune checkpoint in hematological malignancies, in which CD200 expression is associated with poor prog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed017e95d3bfc90884df839327829ca5
https://doi.org/10.1182/blood-2021-153741
https://doi.org/10.1182/blood-2021-153741
Autor:
Andrea Massimiliano Tomirotti, Dorota Komar, Monika Prochorec-Sobieszek, Anna Szumera-Ciećkiewicz, Michał Pawlak, Sonia Dębek, Ewa Lech-Marańda, Przemyslaw Juszczynski, Tomasz Rzymski, Thorsten Stuehmer, Joanna Barankiewicz, Krzysztof Brzózka, Filip Garbicz, Aleksander Salomon-Perzyński, Maciej Szydlowski, Aleksandra Matrejek, Agata Malenda
Publikováno v:
Blood. 136:16-17
The development and progression of multiple myeloma (MM) depend on the formation and perpetual evolution of an immunosuppressive and hypervascular bone marrow microenvironment. MM undergoes an angiogenic switch during its early progression stages and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed76f812f0d7c476c2e6fdff569acc6a
https://doi.org/10.1182/blood-2020-134979
https://doi.org/10.1182/blood-2020-134979
Autor:
Larissa Haertle, Andoni Garitano-Trojaola, Hermann Einsele, Joaquin Martinez Lopez, Umair Munawar, Michal Simicek, Silvia Nerreter, Ricardo Sanchez, Santiago Barrio, Roman Hájek, Leo Rasche, Martin Kortüm, Thomas Haaf, Cornelia Vogt, Matteo DaVia, Marc S. Raab, Nicola Giesen, Thorsten Stuehmer, Max Bittrich
Publikováno v:
Blood. 134:4349-4349
Background: Various treatment regimen in multiple myeloma (MM) are based on proteasome inhibition (PI). Although effective at therapy start, most patients relapse and develop drug resistance over time. To better understand the molecular underpinnings
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fee5f5db85ba9d5010c04f47ac72376
https://doi.org/10.1182/blood-2019-130847
https://doi.org/10.1182/blood-2019-130847
Autor:
Andoni Garitano-Trojaola, Joaquin Martinez-Lopez, Miguel Gallardo, Isabel Cuenca, Cornelia Vogt, Santiago Barrio, Umair Munawar, Hermann Einsele, Matteo Claudio Da Via, Larissa Haertle, Thorsten Stuehmer, Leo Rasche, Martin Kortüm, Lucia Martin
Publikováno v:
Blood. 134:1807-1807
Background: Progression and relapse in Multiple Myeloma (MM) is induced by changes in the clonal tumor composition. In order to better understand the mechanisms underlying these dynamics, we developed clonal competition models based on the co-culture
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfba2f1b720aeaf0060e7788ec83a1ef
https://doi.org/10.1182/blood-2019-130812
https://doi.org/10.1182/blood-2019-130812
Autor:
Marcel Seibold, Ralf C. Bargou, Hermann Einsele, Martin Kortüm, Andreas Schlosser, Anja Mottok, Torsten Steinbrunn, Thorsten Stuehmer, Manik Chatterjee, Andreas Rosenwald, Ellen Leich, Claus J. Scholz
Publikováno v:
Blood. 132:3217-3217
Introduction RAS-associated pathways are promising therapeutic targets in RAS-driven tumors because oncogenic RAS itself is not druggable. Alongside the pathways via PI3K/AKT and RAF/MAPK, the small GTPase RAL is considered to represent a third route
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41cba43f7e8cc54018320a665e076e83
https://doi.org/10.1182/blood-2018-99-119804
https://doi.org/10.1182/blood-2018-99-119804
Autor:
Nadine Rodhes, Raoul Tibes, Andreas Rosenwald, Matteo Claudio Da Via, Andoni Garitano-Trojaola, Thorsten Stuehmer, Eva Teufel, Martin Kortüm, Hermann Einsele, Ana Sancho, Torsten Haferlach, Santiago Barrio Garcia, Jürgen Groll
Publikováno v:
Blood. 132:5148-5148
Secondary Acute Myeloid Leukemia (sAML) accounts for 10-30% of all AML. It arises from a preexisting clonal disorder of hematopoiesis, such as myelodysplastic syndromes (MDS) or chronic myeloproliferative neoplasia (cMPN) in most cases (60-70%) or fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::596f3311fbafd47a5d9e327d7be0bcb4
https://doi.org/10.1182/blood-2018-99-118484
https://doi.org/10.1182/blood-2018-99-118484
Autor:
Thorsten Stuehmer, Hermann Einsele, Max Bittrich, Cornelia Vogt, Torsten Steinbrunn, Matteo Claudio Da Via, Larissa Haertle, K. Martin Kortüm, Umair Munawar, Santiago Barrio Garcia, Andoni Garitano-Trojaola, Thomas Haaf, Joaquin Martinez Lopez, Yanira Ruiz-Heredia, Ramya Potabattula
Publikováno v:
Blood. 132:404-404
Immunomodulatory drugs (IMiDs) and proteasome inhibitors (PI) are backbone agents in the treatment of Multiple Myeloma (MM). However, most patients develop drug resistance over time, with the underlying mechanisms poorly understood. Epigenetic modifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b6fcc2df6707d8046cb52ca1d1fe8e4
https://doi.org/10.1182/blood-2018-99-118944
https://doi.org/10.1182/blood-2018-99-118944
Publikováno v:
Blood. 132:471-471
Mechanisms of drug resistance in Multiple Myeloma (MM) are poorly understood. Mutations and/or changes in the protein expression of the CRBN pathway and proteasome subunits have been identified to induce resistance to IMiDs and PIs. However, only few
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39b58ed9c0ee2f46e30fa9bd06b98dc6
https://doi.org/10.1182/blood-2018-99-118700
https://doi.org/10.1182/blood-2018-99-118700
Autor:
Raoul Tibes, Andreas Rosenwald, Andoni Garitano-Trojaola, Harald Wajant, Eva Teufel, K. Martin Kortüm, Nadine Rodhes, Hermann Einsele, Torsten Haferlach, Matteo Claudio Da Via, Jennifer Kreckel, Santiago Barrio Garcia, Thorsten Stuehmer
Publikováno v:
Blood. 132:5132-5132
Acute Myeloid Leukemia (AML) is a genetically heterogenous disease characterized by clonal expansion of immature myeloid progenitors cells in the bone marrow (BM). Despite this genetic heterogeneity, AML patients share Leukemia associated oncogenes s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a832982ea2590f240b54c36e1de43765
https://doi.org/10.1182/blood-2018-99-118270
https://doi.org/10.1182/blood-2018-99-118270